|
Objective: To study lower extremity deep vein thrombosis (DVT) in patients with plasma high-sensitivity C-reactive protein (Hs-CRP), homocysteine ??(Hcy) levels and DVT correlation explore with inflammation and high half of cystine hyperlipidemia occurrence of DVT development role. The joint detection of high-sensitivity C-reactive protein (Hs-CRP), D-dimer (D-dimer), homocysteine ??(homocysteine, Hcy) levels predict DVT. 3, the analysis of high-sensitivity C-reactive protein (Hs-CRP), D-dimer (D-dimer) level the clinical monitoring role in the process of interventional treatment of DVT. Subjects and methods selected Ningxia Medical University, Department of General Surgery of the Second Affiliated Hospital of DVT patients admitted in November 2009 to October 2010 a total of 80 cases. According to parts of sub-type: central, peripheral, mixed divided into acute, subacute, chronic phase, according to the time of onset. 80 cases randomly selected from the same period in outpatient healthy individuals as a control group, all of the objects are extracted fasting peripheral blood specimens measured high sensitivity C-reactive protein (high-sensitive C-reactive protein Hs-CRP), D-dimer ( D-dimer), homocysteine ??(homocysteine, Hcy) levels. And DVT in patients with indications for surgery patients 54 underwent surgical intervention and catheter thrombolytic therapy, monitoring treatment group after day 1,3,5,7,10,14 and discharged the day of fasting peripheral venous blood measured high sensitivity C-reactive protein (Hs-CRP, high-sensitive C-reactive protein), D-dimer (D-dimer) levels. Into the group of patients need to rule out serious cardiovascular and cerebrovascular diseases, diabetes, thyroid disease, pregnancy, or breast-feeding women and nearly three months inflammation and bleeding, thrombotic diseases. 1, deep venous thrombosis case group patients 50-60 years of age for the peak of predilection. 2 more right lower extremity of the left lower limb DVT is more common (2.75:1). Of DVT group Hs-CRP, Hcy concentration levels significantly higher than the physical examination healthy control groups, significantly higher positive rate of D-dimer. The DVT group parts of sub-type, time of onset installments Hs-CRP, D-dimer various groups contrast there are significant differences in contrast still can not show that the significant difference between the Hcy group. Monitoring Group thrombolytic symptoms patients on admission Hs-CRP, D-Dimer content with thrombolytic therapy of Hs-CRP, D-Dimer levels were significantly higher trend, with a statistically significant difference in admission (P lt; 0.05). With the improvement of symptoms of Hs-CRP, D-Dimer content decreased discharge tends to be normal, and the admission was statistically significant (P lt; 0.05). 5, Hcy Hs-CRP positive correlation (r = 0.605, P lt; 0.01), hs-CRP and D-dimer related (r = 0.434, P lt; 0.01), no Hcy and D-dimer related (r = 0.078, p = 0.644). Multivariate Logistic regression analysis DVT group, Hs-CRP, Hcy into the final equation, Hs-CRP, high Hcy hyperlipidemia may be independent risk factors LEDVT incidence. The Conclusion 1 lower extremity deep vein thrombosis good occurs in the elderly, the left lower limb more than the right lower extremity. High hyperhomocysteinemia, inflammation, and lower extremity deep vein thrombosis related and high hyperhomocysteinemia and inflammation may be an independent risk factor of deep venous thrombosis incidence, suggesting deep venous thrombosis formation of risk factors in addition to the classic three factors say, is the result of both multi-factorial. The DVT of plasma D-Dimer, high-sensitivity C-reactive protein levels with thrombosis of the extension of the time; elevated as to expand the scope and severity of serious thrombosis; clinical D-Dimer, Hs-CRP level changes, to evaluate the state of the patient's thrombosis, can be assisted to determine the sub-type and severity of DVT. 4. Clinical monitoring of D-Dimer, Hs-CRP, with the treatment process, a peak level decreased rapidly after surgery, suggesting DVT patients, thrombolytic therapy 4-5 start after plasma D-Dimer Hs-CRP monitoring, guiding treatment and adjustment of medication.
|